Musculoskeletal evaluation in severe haemophilia A patients from Latin America
Por:
Ozelo M.C., Villaça P.R., Pérez-Bianco R., Candela M., Garcia-Chavez J., Moreno-Rodriguez B., Rodrigues M.B., Rodriguez-Grecco I., Solano M.H., Chumpitaz G., Morales-Gana M.M., Ruiz-Sáez A.
Publicada:
1 ene 2014
Resumen:
There is a paucity of literature on haemophilia treatment in Latin American countries, a region characterized by rapidly improving systems of care, but with substantial disparities in treatment between countries. The aim of this study was to evaluate the musculoskeletal status of haemophilia patients from Latin America and to examine the relationship between musculoskeletal status and treatment practices across countries. The Committee of Latin America on the Therapeutics of Inhibitor Groups conducted a survey of its member country representatives on key aspects of haemophilia treatment in 10 countries. Musculoskeletal status of patients was obtained during routine comprehensive evaluations between March 2009 and March 2011. Eligible patients had severe haemophilia A (factor VIII <1%) without inhibitors (<0.6 BU mL-1) and were =5 years of age. Musculoskeletal status was compared between three groups of countries, based primarily on differences in the availability of long-term prophylaxis. Overall, 143 patients (5-66 years of age) were enrolled from nine countries. In countries where long-term prophylaxis had been available for at least 10 years (Group A), patients aged 5-10 years had significantly better mean World Federation of Hemophilia clinical scores, fewer target joints and fewer affected joints than patients from countries where long-term prophylaxis has been available for about 5 years (Group B) or was not available (Group C). In Latin America, the musculoskeletal status of patients with severe haemophilia without inhibitors has improved significantly in association with the provision of long-term prophylaxis. As more countries in Latin America institute this practice, further improvements are anticipated. © 2013 The Authors.
Filiaciones:
Ozelo M.C.:
Unidade de Hemofilia IHTC 'Claudio L. P. Correa', Instituto Nacional de Tecnologia do Sangue, Hemocentro UNICAMP, University of Campinas, Campinas, Brazil
Villaça P.R.:
Centro de Hemofilia, São Paulo, Brazil
Hospital das Clinicas da Universidade de São Paulo (USP), São Paulo, Brazil
Pérez-Bianco R.:
Instituto de Investigaciones Hematologicas 'Mariano Castex', Academia Nacional de Medicina, Buenos Aires, Argentina
Candela M.:
Instituto de Investigaciones Hematologicas 'Mariano Castex', Academia Nacional de Medicina, Buenos Aires, Argentina
Garcia-Chavez J.:
Unidad Medica de Alta Especialidad, Centro Médico Nacional La Raza, Mexico City, Mexico
Moreno-Rodriguez B.:
Servicio de Hematología, Hospital del Niño, Panama City, Panama
Rodrigues M.B.:
Centro de Hemofilia, São Paulo, Brazil
Hospital das Clinicas da Universidade de São Paulo (USP), São Paulo, Brazil
Rodriguez-Grecco I.:
Centro Hospitalario Pereira Rossell, Hospital de Clinicas, Montevideo, Uruguay
Solano M.H.:
Hospital de San Jose, Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia
Chumpitaz G.:
Hospital Nacional Edgardo Rebagliati M., Lima, Peru
Morales-Gana M.M.:
Hospital Roberto del Rio, Santiago, Chile
Ruiz-Sáez A.:
Centro Nacional de Hemofilia, Banco Municipal de Sangre, Caracas, Venezuela
Hybrid Gold
|